FrancophonIA/ELRC3.0 huggingface dataset:
English: At baseline, 34% of patients were receiving a PI and 60% were receiving an NNRTI.
Maltese: Bħala linja bażi, 34 % tal-pazjenti ħadu PI u 60 % ħadu NNRTI.
English: CD4 Mean Change from Baseline, cells/mm3 at least 5 to < 10 kg (REYATAZ 150 and 200 mg) at least 10 to < 15 kg at least 15 to < 25 kg at least 25 to < 35 kg
Maltese: Bidla Medja fil-CD4 mil-Linja Bażi, ċelloli/mm3 mill-inqas 5 sa <10 kg (REYATAZ 150 u 200 mg) mill-inqas 10 sa <15 kg mill-inqas 15 sa <25 kg mill-inqas 25 sa <35 kg
English: The mechanism of interaction is CYP3A4 and UGT1A1 inhibition.
Maltese: Il-mekkaniżmu ta' interazzjoni huwa linibizzjoni ta' CYP3A4 u UGT1A1.
English: Combination of rifampicin with concomitant low-dose ritonavir (see section 4.5).
Maltese: Il-kombinazzjoni ta' rifampicin ma' ritonavir f'doża baxxa konkomitanti (ara sezzjoni 4.5).
English: Cholelithiasis has been reported in patients receiving REYATAZ (see section 4.8).
Maltese: Kolelitjażi ġiet irrapportata f'pazjenti li kienu qed jirċievu REYATAZ (ara sezzjoni 4.8).
English: REYATAZ 100 mg hard capsules atazanavir
Maltese: REYATAZ 100 mg kapsuli ibsin atazanavir
English: REYATAZ 300 mg hard capsules atazanavir
Maltese: REYATAZ 300 mg kapsuli ibsin atazanavir
English: * When compared to REYATAZ 300 mg and ritonavir 100 mg without nevirapine.
Maltese: * Meta mqabbel ma' REYATAZ 300 mg u ritonavir 100 mg mingħajr nevirapine.
English: Co-administration of REYATAZ with glecaprevir/pibrentasvir fixed dose combination is contraindicated because of the potential increase in the risk of ALT elevations due to a significant increase in glecapreir and pibrentasvir plasma concentrations (see section 4.3).
Maltese: L-għoti flimkien ta' REYATAZ ma' doża fissa kombinata ta' glecaprevir/pibrentasvir huwa kontra-indikat minħabba ż-żieda potenzjali fir-riskju ta' żidiet fl-ALT minħabba żieda sinifikanti fil-konċentrazzjonijiet fil-plażma ta' glecapreir u pibrentasvir (ara sezzjoni 4.3).
English: REYATAZ 200 mg hard capsules atazanavir
Maltese: REYATAZ 200 mg kapsuli ibsin atazanavir
English: Nevirapine 200 mg twice daily (atazanavir 400 mg once daily with ritonavir 100 mg once daily)
Maltese: Nevirapine 200 mg darbtejn kuljum (atazanavir 400 mg darba kuljum ma' ritonavir 100 mg darba kuljum)
English: Atazanavir AUC ↔3% (↓36% ↑67%) Atazanavir Cmax ↑12% (↓33% ↑18%) Atazanavir Cmin ↔3% (↓39% ↑73%)
Maltese: Atazanavir, iddożat siegħa wara ddI+d4T (fi stat sajjem) AUC ta' Atazanavir ↔3 % (↓36 % Cmax ta' Atazanavir ↑12 % (↓33 % Cmin ta' Atazanavir ↔3 % (↓39 %
English: * Effect of atazanavir and ritonavir on the first dose of glecaprevir and pibrentasvir is reported.
Maltese: *Huwa rrappurtat effett ta' atazanavir u ritonavir fuq l-ewwel doża ta' glecaprevir u pibrentasvir.
English: Each bottle contains 60 hard capsules.
Maltese: Kull flixkun fih 60 kapsuli ibsin.
English: Study 045 is a randomised, multicenter trial comparing REYATAZ/ritonavir (300/100 mg once daily) and REYATAZ/saquinavir (400/1,200 mg once daily), to lopinavir + ritonavir (400/100 mg fixed dose combination twice daily), each in combination with tenofovi disoproxil fumarate (see sections 4.5 and 4.8) and one NRTI, in patients with virologic failure on two or more prior regimens containing at least one PI, NRTI, and NNRTI.
Maltese: Studju 045 huwa studju fuq bażi każwali, b'aktar minn ċentru wieħed, fuq bażi każwali li jqabbel REYATAZ/ritonavir (300/100 mg darba kuljum) u REYATAZ/saquinavir (400/1,200 mg darba kuljum), u ma' lopinavir + ritonavir (400/100 mg flimkien f'doża fissa kombinata, darbtejn kuljum), kull waħda flimkien ma' tenofovir disoproxil fumarate (ara sezzjonijiet 4.5 u 4.8) u NRTI wieħed, f' pazjenti li kellhom falliment viroloġiku f'żewġ kuri jew iżjed mogħtija qabel li kien fihom għallinqas PI, NRTI u NNRTI wieħed.
English: Table 1: Dose of REYATAZ oral powder with ritonavir for paediatric patientsa (at least 3 months of age and weighing at least 5 kg)
Maltese: Tabella 1: Doża ta' REYATAZ trab orali ma' ritonavir għal pazjenti pedjatriċia (li għandhom tal-inqas 3 xhur u li jiżnu tal-inqas 5 kg)
English: a The mean baseline CD4 cell count was 337 cells/mm3 (range: 14 to 1,543 cells/mm3) and the mean baseline plasma HIV-1 RNA level was 4.4 log10 copies/ml (range: 2.6 to 5.88 log10 copies/ml).
Maltese: L-għadd taċ-ċelluli CD4 tal-medja tal-linja bażi kien 337 ċellula/mm3 (firxa: minn 14 sa 1,543 ċellula/mm3) u l-livell medju tal-linja bażi tal-plażma HIV-1 RNA kien 4.4 log10 kopji/ml (firxa minn 2.6 sa 5.88 log10 kopji/ml).
English: Atazanavir AUC ↓22% (↓35% ↓6%) * Atazanavir Cmax ↓16% (↓30% ↔0%) * Atazanavir Cmin ↓23% (↓43% ↑2%) *
Maltese: AUC ta' Atazanavir ↓22 % (↓35 % Cmax ta' Atazanavir ↓16 % (↓30 % Cmin ta' Atazanavir ↓23 % (↓43 %
English: The pharmacokinetic data from HIV-infected pregnant women receiving REYATAZ capsules with ritonavir are presented in Table 9.
Maltese: It-tagħrif farmakokinetiku minn nisa tqal infettati bl-HIV li kienu qegħdin jirċievu kapsuli ta' REYATAZ ma' ritonavir huwa ppreżentat fit-Tabella 9.
English: The M184V substitution in reverse transcriptase, which confers resistance to lamivudine and emtricitabine, was detected in 2 subjects in the unboosted REYATAZ and 1 subject in the REYATAZ + ritonavir group.
Maltese: Is-sostituzzjoni M184V f'reverse transcriptase, li tagħti reżistenza lil lamivudine u lil emtricitabine, instabet f'żewġ individwi fil-grupp ta' REYATAZ mhux imsaħħaħ u f'individwu wieħed fil-grupp ta' REYATAZ + ritonavir.
English: Reduced plasma concentrations of atazanavir may be the consequence of increased gastric pH if antacids, including buffered medicinal products, are administered with REYATAZ.
Maltese: Il-konċentrazzjonijiet imnaqqsa ta' atazanavir fil-plażma jistgħu jkunu lkonsegwenza ta' żieda fil-pH gastriku jekk antaċidi, inklużi prodotti mediċinali buffered jingħataw ma' REYATAZ.
English: Although not studied, there is a potential for an increase in pravastatin or fluvastatin exposure when coadministered with protease inhibitors.
Maltese: Għalkemm ma ġiex studjat, hemm potenzjal għal żieda fl-esponiment għal pravastatin or fluvastatin meta jingħataw flimkien ma' inibituri talprotease.
English: Co-administration of lurasidone with REYATAZ is contraindicated as this may incrrease lurasidone-related toxicity (see section 4.3)
Maltese: L-għoti flimkien ta' lurasidone ma' REYATAZ huwa kontraindikat għaliex dan jista' jżid ittossiċità relatata ma' lurasidone (ara sezzjoni 4.3).
English: The mechanism of interaction between atazanavir and tenofovir disoproxil fumarate is unknown.
Maltese: Il-mekkaniżmu ta' interazzjoni bejn atazanavir u tenofovir disoproxil fumarate mhuwiex magħruf.
English: - in patients without a functional CYP2C19 allele, close clinical and laboratory monitoring of voriconazole-associated adverse events is recommended.
Maltese: - f'pazjenti mingħajr allele CYP2C19 funzjonali, monitoraġġ kliniku u tallaboratorju mill-qrib ta' każijiet avversi assoċjati ma' voriconazole hu rakkomandat.
English: The mechanism of efavirenz/atazanavir interaction is CYP3A4 induction.
Maltese: Il-mekkaniżmu talinterazzjoni ta' efavirenz/atazanavir huwa l-induzzjoni ta' CYP3A4. ** Fuq il-bażi ta' paragun storiku.
English: During the second and third trimesters of pregnancy:
Maltese: Matul it-tieni u t-tielet trimestru tat-tqala:
English: Ethinyloestradiol AUC ↓19% (↓25% Ethinyloestradiol Cmax ↓16% (↓26% Ethinyloestradiol Cmin ↓37% (↓45%
Maltese: AUC ta' Ethinyloestradiol↓19 % Cmax ta' Ethinyloestradiol ↓16 % Cmin ta' Ethinyloestradiol ↓37 %
English: For patients who are taking tenofovir disoproxil fumarate, if REYATAZ/ritonavir with both tenofovir disoproxil fumarate and an H2-receptor antagonist are co-administered, a dose increase of REYATAZ to 400 mg with 100 mg of ritonavir is recommended.
Maltese: REYATAZ/ritonavir kemm ma' tenofovir disoproxil fumarate kif ukoll ma' antagonist ta' riċettur H2 jingħataw flimkien, hija rakkomandata żieda fid-doża ta' REYATAZ għal 400 mg ma' 100 mg ta' ritonavir.
English: The mechanism of this decrease is unknown (see sections 4.2 and 4.4.
Maltese: Il-mekkaniżmu ta' dan it-tnaqqis mhuwiex magħruf (ara sezzjonijiet 4.2 u 4.4.)
English: REYATAZ capsules are available for paediatric patients at least 6 years of age who weigh at least 15 kg and who are able to swallow capsules (see Summary of Product Characteristics for REYATAZ
Maltese: REYATAZ kapsuli huma disponibbli għal pazjenti pedjatriċi li għandhom tal-inqas 6 snin ta' età li jiżnu minn tal-inqas 15 kg u li jistgħu jibilgħu l-kapsuli(ara s-Sommarju tal-Karatteristiċi tal-Prodott għall-kapsuli ta' REYATAZ).
English: What REYATAZ looks like and contents of the pack
Maltese: Id-dehra ta' REYATAZ u l-kontenuti tal-pakkett
English: Swallow the capsules whole.
Maltese: Tiftaħx il-kapsuli.
English: An initial dose reduction of diltiazem by 50% is recommended, with subsequent titration as needed and ECG monitoring.
Maltese: Huwa rakkomandat tnaqqis inizjali tad-doża ta' diltiazem b'50 %, b'titrazzjoni sussegwenti kif meħtieġ u monitoraġġ tal-ECG.
English: The mechanism of interaction is a reduced solubility of atazanavir with increasing pH related to the presence of anti-acid agent in didanosine buffered tablets.
Maltese: Il-mekkaniżmu ta' interazzjoni huwa solubilità mnaqqsa ta' atazanavir hekk kif tiżdied il-pH relatata mal-preżenza ta' sustanza kontra l-aċidi fil-pilloli buffered ta' didanosine.
English: When compared to atazanavir 300 mg with ritonavir 100 mg without tenofovir disoproxil fumarate, atazanavir concentrations are expected to be additionally decreased by about 20%.
Maltese: Meta mqabbel ma' atazanavir 300 mg ma' ritonavir 100 mg mingħajr tenofovir disoproxil fumarate, ilkonċentrazzjonijiet ta' atazanavir huma mistennija li jonqsu b'mod addizzjonali b'madwar 20 %.
English: b REYATAZ/RTV with tenofovir disoproxil fumarate/emtricitabine (fixed dose 300 mg/200 mg tablets once daily).
Maltese: b REYATAZ/RTV ma' tenofovir disoproxil fumarate/emtricitabine (pilloli ta' doża fissa ta' 300 mg/200 mg darba kuljum).
English: In clinical trials of antiretroviral treatment naive patients treated with boosted atazanavir, the I50L substitution did not emerge in any patient without baseline PI substitutions.
Maltese: F'esperimenti kliniċi ta' pazjenti li qatt qabel ma ħadu kura antiretrovirali li ġew ittratati b'atazanavir ibbustjat, is- sostituzzjonijiet I50L ma dehritx fl-ebda pazjent mingħajr sostituzzjonijiet PI tal-linja bażi.
English: Each capsule contains 200 mg of atazanavir (as sulphate).
Maltese: Kull kapsula fiha 200 mg atazanavir (bħala sulphate).
English: postpartuma (n=36)
Maltese: wara t-twelida (n=36)
English: Table 7: Efficacy Outcomes (paediatric patients 6 years to less than 18 years of age) at Week 48 (Study AI424-020)
Maltese: f'Ġimgħa 48 (Studju AI424-020)
English: Famotidine 20 mg twice daily Atazanavir AUC ↓21% (↓34% ↓4%) * Atazanavir Cmax ↓21% (↓36% ↓4%) * Atazanavir Cmin ↓19% (↓37% ↑5%) *
Maltese: AUC ta' Atazanavir ↓21% (↓34% Cmax ta' Atazanavir ↓21 % (↓36 % Cmin ta' Atazanavir ↓19% (↓37% ↑5%)
English: No dosage adjustments are needed for REYATAZ/ritonavir and fluconazole.
Maltese: M'hemmx bżonn ta' aġġustamenti għad-doża għal REYATAZ/ritonavir u fluconazole.
English: Off white to pale yellow powder.
Maltese: Staqsi lill-ispiżjar għal siringa orali.
English: *Ritonavir capsules, tablets or oral solution may be used.
Maltese: *Kapsuli, pilloli jew s-soluzzjoni orali ta' ritonavir jistgħu jintużaw.
English: What REYATAZ looks like and contents of the pack Each capsule of REYATAZ 150 mg contains 150 mg atazanavir.
Maltese: Kull kapsula ta' REYATAZ 150 mg fiha 150 mg atazanavir.
English: Famotidine 40 mg twice daily Atazanavir AUC ↓24% (↓36% ↓11%)* Atazanavir Cmax ↓23% (↓36% ↓8%) * Atazanavir Cmin ↓25% (↓47% ↑7%) *
Maltese: AUC ta' Atazanavir ↓24 % (↓36 % Cmax ta' Atazanavir ↓23% (↓36 % Cmin ta' Atazanavir ↓25% (↓47% ↑7%)
English: Atazanavir AUC ↑43% (↑30% ↑57%) Atazanavir Cmax ↑12% (↑1% ↑24%) Atazanavir Cmin ↑23% (↑13% ↑134%) Grazoprevir AUC: ↑958% (↑678% Grazoprevir Cmax: ↑524% (↑342% Grazoprevir Cmin: ↑1064% (↑696%
Maltese: AUC ta' Atazanavir ↑7% (↓2% ↑17%) Cmax ta' Atazanavir ↑2% (↓4% ↑8%) Cmin ta' Atazanavir ↑15% (↑2% ↑29%) AUC ta' Elbasvir: ↑376% (↑307% Cmax ta' Elbasvir:
English: The mean baseline CD4 cell count was 214 cells/mm3 (range: 2 to 810 cells/mm3) and mean baseline plasma HIV-1 RNA was 4.94 log10 copies/ml (range: 2.6 to 5.88 log10 copies/ml).
Maltese: L-għadd ta' ċelloli CD4 fil-linja bażi kien ta' 214-il ċellola/mm3 (medda: bejn 2 u 810 ċelloli/mm3) u l-linja bażi medja ta ' HIV-1 RNA fil-plażma kienet ta' 4.94 log10 kopja/ml (medda: bejn 2.6 u 5.88 log10 kopja/ml).
English: Tel.: + 48 22 5796666
Maltese: Τηλ: + 357 800 92666
English: The recommended adult dose of REYATAZ capsules is 300 mg once daily with 100 mg ritonavir once daily and with food, in combination with other anti-HIV medicines.
Maltese: Id-doża rakkomandata għall-adulti tal-kapsuli ta' REYATAZ hija normalment ta' 300 mg darba kuljum ma' 100 mg ritonavir darba kuljum u mal-ikel, flimkien ma' mediċini oħra ta' kontra l-HIV.
English: PDE5 inhibitors used for the treatment of erectile dysfunction: particular caution should be used when prescribing PDE5-inhibitors (sildenafil, tadalafil, or vardenafil) for the treatment of erectile dysfunction in patients receiving REYATAZ.
Maltese: Inibituri PDE5 użati għall-kura ta' disfunzjoni erettili: għandha tingħata attenzjoni partikolari meta jingħataw inibituri-PDE5 (sildenafil, tadalafil, jew vardenafil) b'riċetta ta' tabib għall-kura ta' disfunzjoni erettili f'pazjenti li jirċievu REYATAZ.
English: Each capsule contains 100 mg of atazanavir (as sulphate).
Maltese: Kull kapsula fiha 100 mg atazanavir (bħala sulphate).
English: b ATV/RTV with tenofovir disoproxil fumarate/emtricitabine (fixed dose 300 mg/200 mg tablets once daily).
Maltese: b ATV/RTV b'tenofvir/disoproxil fumarate/emtricitabine (doża fissa ta' pilloli 300 mg/200 mg darba kuljum).
English: Each capsule contains 300 mg of atazanavir (as sulphate).
Maltese: Kull kapsula fiha 300 mg atazanavir (bħala sulphate).
English: Co-administration with REYATAZ/ritonavir may result in increased concentrations of the PDE5 inhibitor and an increase in PDE5inhibitor-associated adverse events.
Maltese: L-għoti fl-istess ħin ta' REYATAZ/ritonavir jista' jirriżulta f'konċentrazzjonijiet miżjudin talinibitur PDE5 u żieda fl-episodji avversi assoċjati mal-inibitur PDE5.
English: uncommon: weight decreased, weight gain, anorexia, appetite increased
Maltese: mhux komuni: tnaqqis fil-piż, żieda fil-piż, anoreksja, żieda fl-aptit
English: Rifabutin 150 mg twice weekly (atazanavir 300 mg and ritonavir 100 mg once daily)
Maltese: Rifabutin 150 mg darbtejn filġimgħa (atazanavir 300 mg u ritonavir 100 mg darba kuljum)
English: c Lopinavir/RTV with tenofovir disoproxil fumarate/emtricitabine (fixed dose 300 mg/200 mg tablets once daily).
Maltese: c Lopinavir/RTV ma' tenofovir disoproxil fumarate/emtricitabine (pilloli ta' doża fissa ta' 300 mg/200 mg darba kuljum).
English: Atazanavir (am): 1 hr after omeprazole Atazanavir AUC ↓30% (↓43% ↓14%) * Atazanavir Cmax ↓31% (↓42% ↓17%) * Atazanavir Cmin ↓31% (↓46% ↓12%) *
Maltese: AUC ta' Atazanavir ↓30% (↓43% Cmax ta' Atazanavir ↓31% (↓42% ↓17%) Cmin ta' Atazanavir ↓31% (↓46% ↓12%)
English: Famotidine 40 mg twice daily Atazanavir AUC ↓23% (↓32% ↓14%) Atazanavir Cmax ↓23% (↓33% ↓12%) Atazanavir Cmin ↓20% (↓31% ↓8%) In Healthy volunteers with atazanavir/ritonavir at an increased dose of 400/100 mg once daily Famotidine 40 mg twice daily Atazanavir AUC ↔3% (↓14% ↑22%) Atazanavir Cmax ↔2% (↓13% ↑8%) Atazanavir Cmin ↓14% (↓32% ↑8%)
Maltese: AUC ta' Atazanavir ↔3 % (↓14% Cmax ta' Atazanavir ↔2% (↓13% ↑8%) Cmin ta' Atazanavir ↓14 % (↓32 % B'Tenofovir disoproxil fumarate 300 mg darba kuljum (ekwivalenti għal 245 mg tenofovir disoproxil) F'pazjenti infettati bl-HIV, b'atazanavir/ritonavir bid-doża rakkomandata ta' 300/100 mg darba kuljum
English: Lamotrigine should be used with caution in combination with REYATAZ/ritonavir.
Maltese: Lamotrigine għandu jintuża b'kawtela f'kombinazzjoni ma' REYATAZ/ritonavir.
English: a Mean baseline CD4 cell count was 214 cells/mm3 (range 2 to 810 cells/mm3) and mean baseline plasma HIV-1 RNA was 4.94 log10 copies/ml (range 2.6 to 5.88 log10 copies/ml)
Maltese: L-għadd ta' ċelloli CD4 fil-linja bażi kien ta' 214-il ċellola/mm3 (medda: bejn 2 u 810 ċelloli/mm3) u l-linja bażi medja ta ' HIV-1 RNA fil-plażma kienet ta' 4.94 log10 kopja/ml (medda: bejn 2.6 u 5.88 log10 kopja/ml)
English: Chronic kidney disease
Maltese: Riżultati kliniċi
English: rare: hepatosplenomegaly, cholecystitis a
Maltese: rari: is-sindromu ta' Stevens-Johnson a,b
English: Although this study presented some limitations (i.e., unbound drug concentrations not studied), results suggested that the atazanavir pharmacokinetic parameters were decreased by 30% to 50% in patients undergoing haemodialysis compared to patients with normal renal function.
Maltese: Għalkemm dan l-istudju kellu xi limitazzjonijiet (i.e., konċentrazzjonijiet ta' mediċina mhux imwaħħla ma kinux studjati), ir-riżultati ssuġġerew li l-parametri farmakokinetiċi ta' atazanavir tnaqqsu bi 30 % sa 50 % tal-pazjenti li kienu fuq l-emodijalisi meta mqabbel ma' pazjenti b'funzjoni normali tal-kliewi.
English: f Intent-to-treat analysis, with missing values considered as failures.
Maltese: f Analiżi ta' dawk bil-Ħsieb li jiġu kkurati, bil-valuri nieqsa kkunsidrati bħala fallimenti.
English: Midazolam Triazolam
Maltese: Indikazzjonijiet terapewtiċi
English: Serum concentrations of verapamil may be increased by REYATAZ/ritonavir due to CYP3A4 inhibition.
Maltese: Il-konċentrazzjonijiet ta' verapamil fis-serum jistgħu jiżdiedu b'REYATAZ/ritonavir minħabba linibizzjoni ta' CYP3A4.
English: Withdrawal of ritonavir only under restrictive conditions The recommended standard treatment is REYATAZ boosted with ritonavir, ensuring optimal pharmacokinetic parameters and level of virologic suppression.
Maltese: Il-kura standard rakkomandata hija REYATAZ imsaħħaħ b'ritonavir, li din tiżgura l-aqwa parametri farmakokinetiċi u livell ta' soppressjoni viroloġika.
English: REYATAZ oral powder, co-administered with low dose ritonavir, is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected paediatric patients at least 3 months of age and weighing at least 5 kg (see section 4.2).
Maltese: REYATAZ trab orali, li jingħata flimkien ma' doża baxxa ta' ritonavir, huwa indikat flimkien ma' prodotti mediċinali antiretrovirali oħra għall-kura ta' pazjenti pedjatriċi infettati bl-HIV-1 li għandhom tal-inqas 3 xhur u li jiżnu tal-inqas 5 kg (ara sezzjoni 4.2).
English: Overall in this study, 182 paediatric patients (81 antiretroviral-naive and 101 antiretroviral-experienced) received once daily REYATAZ (capsule or powder formulation), with or without ritonavir, in combination with two NRTIs.
Maltese: Globalment f'dan l-istudju, 182 pazjent pedjatriku (81 pazjent li qatt ma kienu kkurati b'antiretrovirali fil-passat u 101 li kienu kkurati b'antiretrovirali fil-passat), irċivew
English: B. PACKAGE LEAFLET
Maltese: c PI maġġuri
English: other medicines to treat HIV infection (e.g. indinavir, nevirapine and efavirenz) boceprevir and sofosbuvir/velpatasvir/voxilaprevir (used to treat hepatitis C) sildenafil, vardenafil, or tadalafil (used by men to treat impotence (erectile dysfunction)) if you are taking an oral contraceptive ("the Pill") with REYATAZ to prevent pregnancy, be sure to take it exactly as instructed by your doctor and not miss any doses any medicines used to treat diseases related to the acid in the stomach (e.g. antacids to be taken 1 hour before taking REYATAZ or 2 hours after taking REYATAZ, H2-blockers like famotidine and proton pump inhibitors like omeprazole) medicines to lower blood pressure, to slow heart rate, or to correct heart rhythm (amiodarone, diltiazem, systemic lidocaine, verapamil) atorvastatin, pravastatin, and fluvastatin (used to lower blood cholesterol) salmeterol (used to treat asthma) cyclosporin, tacrolimus, and sirolimus (medicines to decrease the effects of body's immune system) certain antibiotics (rifabutin, clarithromycin) ketoconazole, itraconazole, and voriconazole (antifungals) warfarin (anticoagulant, used to reduce the blood clots) carbamazepine, phenytoin, phenobarbital, lamotrigine (antiepileptics) irinotecan (used to treat cancer) sedative agents (e.g. midazolam administered by injection) buprenorphine (used to treat opioid addiction and pain).
Maltese: mediċini oħra għal kura ta' l-infezzjoni ta' l-HIV (eż. indinavir, nevirapine u efavirenz) boceprevir u sofosbuvir/velpatasvir/voxilaprevir (jintużaw biex jikkuraw epatite C) sildenafil, vardenafil, jew tadalafil (jintuża mill-irgiel kontra l-impotenza (anormalità erettili)) jekk qed tieħu kontraċettiv orali (“Il-Pill”) ma' REYATAZ biex tiġi evitata tqala, aċċerta ruħek li teħodha eżatt kif ikun tak parir it-tabib tiegħek u tinsa tieħu l-ebda doża kull mediċina użata biex tikkura mard relatat mal-aċidu fl-istonku (eż. antaċidi li għandhom jittieħdu siegħa qabel REYATAZ jew sagħtejn wara li tieħu REYATAZ, imblokkaturi ta' H2 bħal famotidine u inibituri proton pump bħal omeprazole) mediċini biex ibaxxu l-pressjoni, ir-rata tat-taħbit tal-qalb, jew biex jirranġaw ir-ritmu tal-qalb (amiodarone, diltiazem, lidocaine sistemiku, verapamil) atorvastatin, pravastatin, u fluvastatin (biex ibaxxu l-livell tal-kolesterol fid-demm) salmeterol (użat għall-kura tal-ażżma) cyclosporine, tacrolimus, u sirolimus (mediċini biex inaqqsu l-effetti tas-sistema ta' l-immunità tal-ġisem) xi antibijotiċi (rifabutin, clarithromycin) ketoconazole, itraconazole, u voriconazole (antifungali) warfarin (antikoagulanti użat biex irattab id-demm) carbamazepine, phenytoin, phenobarbiral, lamotrigine (antiepilettiċi) irinotecan (użat fil-kura tal-kanċer) mediċini li jikkalmaw (eż. midazolam mogħti b'injezzjoni) buprenorphine (użat biex jittratta dipendenza fuq l-opjojde u uġigħ).
English: Quinidine has a narrow therapeutic window and is contraindicated due to potential inhibition of CYP3A by REYATAZ.
Maltese: Quinidine għandu perjodu terapewtiku dejjaq u huwa kontraindikat minħabba linibizzjoni potenzjali ta' CYP3A minn REYATAZ.
English: c LPV/RTV with tenofovir disoproxil fumarate/emtricitabine (fixed dose 300 mg/200 mg tablets once daily).
Maltese: c LPV/RTV b'tenofovir disoproxil fumarate/emtricitabine (doża fissa ta' pilloli ta' 300 mg/200 mg darba kuljum).
English: Your doctor will evaluate how severe your liver disease is before deciding whether you can take REYATAZ if you are taking any of these medicines: see also Other medicines and REYATAZ rifampicin (an antibiotic used to treat tuberculosis) astemizole or terfenadine (commonly used to treat allergy symptoms, these medicines may be available without prescription); cisapride (used to treat gastric reflux, sometimes called heartburn); pimozide (used to treat schizophrenia); quinidine or bepridil (used to correct heart rhythm); ergotamine, dihydroergotamine, ergonovine, methylergonovine (used to treat headaches); and alfuzosin (used to treat enlarged prostatic gland) quetiapine (used to treat schizophrenia, bipolar disorder and major depressive disorder); lurasidone (used to treat schizophrenia) medicines containing St. John's wort (Hypericum perforatum, a herbal preparation)
Maltese: It-tabib tiegħek sejjer jevalwa kif inhi l-marda tal-fwied tiegħek qabel ma jiddeċiedi tistax tieħu REYATAZ jekk qed tieħu xi waħda minn dawn il-mediċini: aqra wkoll Mediċini oħra u REYATAZ rifampicin (antibijotiku li jintuża kontra t-tuberkulosi) astemizole jew terfenadine (jintuza ħafna kontra sintomi ta' allerġija, dawn il-mediċini jistgħu jingħataw mingħajr riċetta); cisapride (jintuża kontra rifluss gastriku, xi kultant imsejjaħ ħruq ta' stonku); primozide (jintuża għall-iskizofrenija); quinidine jew bepridil (jintuża biex jikkoreġi r-ritmu tal-qalb); ergotamine, dihydroergotamine, ergonovine, methylergonovine (jintużaw għal uġigħ ta' ras); u alfuzosin (użat biex jikkura glandola prostatika minfuħa) quetiapine (użat biex jikkura skizofrenja, disturb bipolari u disturb dipressiv maġġuri); lurasidone (użat biex jikkura skizofrenja) mediċini li fihom St.